The recommended weekly dose in milligrams (mg) per kilogram (kg) of body weight for pediatric patients is: Pediatric GH Deficiency: 0.18 mg/kg/week to 0.3 mg/kg/week (0.026 mg/kg/day to 0.043 mg/kg/day) Turner syndrome: Up to 0.375 mg/kg/week (up to 0.054 mg/kg/day) Idiopathic short stature: Up to 0.37 mg/kg/week (up to 0.053 mg/kg/day) SHOX Deficiency: 0.35 mg/kg/week (0.05 mg/kg/day) Small for Gestational Age (SGA): Up to 0.47 mg/kg/week (up to 0.067 mg/kg/day) In very short pediatric patients, HSDS less than -3, and older pubertal pediatric patients consider initiating treatment with a larger dose of ZOMACTON 5mg IU injection (up to 0.067 mg/kg/day)
Because 5-amino-1MQ is not a compounding-pharmacy-accessible substance and is not an FDA-approved therapy, the safety discussion is primarily about what physicians should tell patients asking about it, rather than about clinical monitoring parameters for active therapy
Bevilacqua, Arturo, and Mariano Bizzarri
The disconnect between preclinical efficacy and human clinical outcomes remains unexplained and represents a significant limitation for potential therapeutic applications
NNMT methylates nicotinamide (a form of vitamin B3) using S-adenosylmethionine (SAM) as the methyl donor
Vitamin B12 deficiency in over 16s: diagnosis and management (NG239) Rationale and impact
